Frank X. Leonard
CIK: 0001822879
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovoCure Ltd
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Jun 30, 2026NVCR
NovoCure Ltd
Award(A)Direct1.9K shares at avg. $11.15$21K - Jun 4, 2026NVCR
NovoCure Ltd
Sale(S)Direct34.3K shares at avg. $17.93$615K - Mar 4, 2026NVCR
NovoCure Ltd
Sale(S)Direct5.6K shares at avg. $13.31$75K - Mar 3, 2026NVCR
NovoCure Ltd
Award(A)Direct150K shares- - Mar 2, 2026NVCR
NovoCure Ltd
Sale(S)Direct7.2K shares at avg. $13.49$98K - Feb 28, 2026NVCR
NovoCure Ltd
Award(A)Direct18.6K shares- - Feb 27, 2026NVCR
NovoCure Ltd
Sale(S)Direct9.7K shares at avg. $13.66$133K - Nov 1, 2025NVCR
NovoCure Ltd
Tax Payment(F)Direct966 shares at avg. $12.81$12K - Jun 30, 2025NVCR
NovoCure Ltd
Award(A)Direct833 shares at avg. $15.13$13K - Jun 4, 2025NVCR
NovoCure Ltd
Award(A)Direct179.4K shares- - Jun 2, 2025NVCR
NovoCure Ltd
Sale(S)Direct21.7K shares at avg. $17.22$374K - Jun 2, 2025NVCR
NovoCure Ltd
Sale(S)Direct1.9K shares at avg. $19.01$36K - Jun 2, 2025NVCR
NovoCure Ltd
Sale(S)Direct6.6K shares at avg. $17.99$119K - Mar 4, 2025NVCR
NovoCure Ltd
Award(A)Direct55K shares at avg. $18.19$1000K - Mar 3, 2025NVCR
NovoCure Ltd
Sale(S)Direct2.5K shares at avg. $18.54$47K - Feb 28, 2025NVCR
NovoCure Ltd
Sale(S)Direct2.8K shares at avg. $18.28$51K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct10.3K shares at avg. $19.92$205K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct2K shares at avg. $20.55$41K - Nov 1, 2024NVCR
NovoCure Ltd
Sale(S)Direct598 shares at avg. $15.94$10K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 | NVCR NovoCure Ltd | Award(A) | 1,905 | $11.15 | $21,241 | Direct |
| Jun 4, 2026 | NVCR NovoCure Ltd | Sale(S) | 34,273 | $17.93 | $614,635 | Direct |
| Mar 4, 2026 | NVCR NovoCure Ltd | Sale(S) | 5,607 | $13.31 | $74,603 | Direct |
| Mar 3, 2026 | NVCR NovoCure Ltd | Award(A) | 150,000 | - | $0 | Direct |
| Mar 2, 2026 | NVCR NovoCure Ltd | Sale(S) | 7,232 | $13.49 | $97,581 | Direct |
| Feb 28, 2026 | NVCR NovoCure Ltd | Award(A) | 18,621 | - | $0 | Direct |
| Feb 27, 2026 | NVCR NovoCure Ltd | Sale(S) | 9,734 | $13.66 | $133,003 | Direct |
| Nov 1, 2025 | NVCR NovoCure Ltd | Tax Payment(F) | 966 | $12.81 | $12,374 | Direct |
| Jun 30, 2025 | NVCR NovoCure Ltd | Award(A) | 833 | $15.13 | $12,603 | Direct |
| Jun 4, 2025 | NVCR NovoCure Ltd | Award(A) | 179,426 | - | - | Direct |
| Jun 2, 2025 | NVCR NovoCure Ltd | Sale(S) | 21,717 | $17.22 | $373,958 | Direct |
| Jun 2, 2025 | NVCR NovoCure Ltd | Sale(S) | 1,879 | $19.01 | $35,722 | Direct |
| Jun 2, 2025 | NVCR NovoCure Ltd | Sale(S) | 6,600 | $17.99 | $118,733 | Direct |
| Mar 4, 2025 | NVCR NovoCure Ltd | Award(A) | 54,975 | $18.19 | $999,995 | Direct |
| Mar 3, 2025 | NVCR NovoCure Ltd | Sale(S) | 2,527 | $18.54 | $46,841 | Direct |
| Feb 28, 2025 | NVCR NovoCure Ltd | Sale(S) | 2,770 | $18.28 | $50,648 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 10,277 | $19.92 | $204,737 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 1,989 | $20.55 | $40,872 | Direct |
| Nov 1, 2024 | NVCR NovoCure Ltd | Sale(S) | 598 | $15.94 | $9,531 | Direct |
1-19 of 19 transactions
About Leonard Frank X
Leonard Frank X (SEC CIK 0001822879) files insider reports with the SEC as Chief Executive Officer of NovoCure Ltd (NVCR).
Signal8 holds 13 ownership filings by Leonard Frank X, all Form 4s, filed between Nov 4, 2024 and Jul 1, 2026. Those filings report 19 transactions, from Nov 1, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Leonard Frank X's filings is in WAYNE, PA.
Recent filings by Leonard Frank X
- Jun 30, 2026: Grant or award of NVCR shares (Form 4, code A).
- Jun 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 3, 2026: Grant or award of NVCR shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of NVCR shares (Form 4, code S).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director
- Ocean Allyson J, Director